Glucagon-like peptide-1 (GLP-1) analogues

PheWeb

GLP1ANA

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Medicine purchases: ATC A10BH

16740

Check pre-conditions, main-only, mode, ICD version None

14480

Check minimum number of events

Min. number of events 3

14480

Include endpoints None

14480

GLP1ANA

Extra metadata

First used in FinnGen datafreeze DF2

Similar endpoints

↥

List of similar endpoints to Glucagon-like peptide-1 (GLP-1) analogues based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	14022	6166	7856
Unadjusted prevalence (%)	4.54	3.55	5.82
Mean age at first event (years)	65.34	64.90	65.68

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.05	3.86 [3.27, 4.57]	4.9e-56	1288
15 years	0.01	1.19 [0.99, 1.44]	6.8e-2	386
5 years	0.00	4.55 [3.88, 5.34]	9.5e-78	771
1 year	0.00	3.87 [3.10, 4.83]	5.7e-33	132

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: GLP1ANA – Glucagon-like peptide-1 (GLP-1) analogues
GWS hits:

Survival analyses between endpoints

↥

Plot

before Glucagon-like peptide-1 (GLP-1) analogues
after Glucagon-like peptide-1 (GLP-1) analogues

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Glucagon-like peptide-1 (GLP-1) analogues

↥